Of the 3 currently accepted approaches for the treatment of DME: 1) focal laser 2) steroids, and 3) anti-VEGF, none are optimal, none fully address the root cause of DME, (i.e. target VEGF and not the underlying genesis of DME; inflammation) and all are associated with significant limitations:
- All are less than 40% effective and carry adverse side effects that can also lead to vision loss.
- All until recently have been used as monotherapy.
- Direct injection into the eye or sustained release implants remains the most important limitation of many of these new treatments.
- Retinal specialists are looking for new and alternative therapeutics that can be administered without the requirement for repeated and chronic injections every 4-6 weeks AND without the side effects of steroids (cataracts and steroid induced glaucoma).